Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Watch the webcasts
Course Directors: Raffaele De Caterina (IT), Erik L. Grove (DK), Steen D. Kristensen (DK), Marco Zimarino (IT)
Faculty: Jean-Philippe Collet (FR), Kurt Huber (AU), David J. Moliterno (USA), Joao Morais (PT), Franz-Josef Neumann (GE), Giuseppe Patti (IT), Bianca Rocca (IT), Helmut Schühlen (GE), Robert F. Storey (UK)
12:30-14:00: Arrival at the European Heart House and Lunch14:00-14:10: Welcome – R. De Caterina, S.D. KristensenSESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY – Chairs: E. Grove and R. De CaterinaUnderstanding Thrombosis in...14:10-14:25 Acute Coronary Syndromes – S.D. Kristensen14:25-14:30 Discussion14:30-14:45 Venous Thromboembolism – J. Morais14:45-14:50 Discussion14:50-15:05 Atrial fibrillation – R. De Caterina15:05-15:10 DiscussionMethodology15:10-15:20 Platelet function testing – B. Rocca15:20-15:30 Evaluating Coagulation – E. Grove15:30-15:45 Discussion15:45-16:15 Coffee break SESSION 2: ACS - ACUTE THERAPY (before the cath lab, in the cath lab, and when a cath lab is not available) – Chairs: M. Zimarino and S.D. Kristensen16:15-16:30 ESC Guidelines: focus on oral antiplatelet therapy before and in the cath lab – S.D. Kristensen16:30-16:40 Discussion16:40-16:50 Pretreatment with oral P2Y12 inhibitors in NSTEMI and STEMI - against – J-P. Collet16:50-17:00 Pretreatment with oral P2Y12 inhibitors in NSTEMI and STEMI - in favour – M. Zimarino17:00-17:15 Discussion17.15-17:40 Intravenous antithrombotic agents: bivalirudin, fondaparinux, LMWH, glycoprotein IIb/IIIa inhibitors, cangrelor - D.J. Moliterno 17:40-18:00 Discussion20:00-22:00 Group Dinner
SESSION 3: ACS AFTER THE STORM - ORAL ANTIPLATELET AGENTS – Chairs: D.J. Moliterno and K. Huber09:00-09:15 ESC Guidelines – drug therapy after the cath lab – J-P. Collet09:15-09:20 Discussion 09:20-09:35 Duration of DAPT in ACS – R.F. Storey09:35-09:40 Discussion09:40-09:55 Thrombin receptor antagonists and other new oral antiplatelet drugs - D.J. Moliterno 09:55-10:10 Discussion10:10-10:30 Coffee breakSESSION 4: CORONARY INTERVENTIONS 2017 – Chairs: R. Storey and D.J. Moliterno 10:30-10:45 Thrombectomy – how? For whom? – M. Zimarino10:45-10:50 Discussion10:50-11:05 DES or maybe BMS – which one(s)? – H. Schühlen11:05-11:10 Discussion11:10-11:25 Bioresorbable stents – for all or for few? – F-J. Neumann11:25-11:30 DiscussionSESSION 5: STABLE CAD – Chairs: S.D. Kristensen and K. Huber 11:30-11:40 Optimal medical therapy in patients with stable CAD – R.F. Storey11:40-11:45 Discussion11:45-11:55 FFR? FFR-CT? Ischaemia testing? – M. Zimarino11:55-12:00 Discussion12:00-12:10 Duration of DAPT in Stable CAD after PCI – H. Schühlen12:10-12:15 Discussion12:15-16:00 LUNCH AND EXTRAMURAL MEET-THE-EXPERTS SESSIONSESSION 6: NOACs BEYOND ATRIAL FIBRILLATION – Chairs: B. Rocca and K. Huber 16:00-16:15 The pharmacology of NOACs (including antidotes) – B. Rocca16:15-16:20 Discussion16:20-16:35 NOACs in VTE - drug selection according to patient’s risk profile and duration of therapy – J. Morais16:35-16:40 Discussion16:40-16:55 NOACs in ACS – R. De Caterina16:55-17:00 Discussion17:00-17:15 Coffee breakSESSION 4: ATRIAL FIBRILLATION I – Chairs: J. Morais and B. Rocca 17:15-17:30 Warfarin or NOACs – Lessons from real-life data in different countries – G. Patti17:30-17:35 Discussion17:35-17:50 LAA occluders: for whom? – E. Grove17:50-17:55 Discussion17:55-18:10 Peri-cardioversion and peri-ablation anticoagulation – G. Patti18:10-18:25 Discussion
SESSION 8: DIFFICULT CLINICAL CASES – Chairs: M. Zimarino and E. GroveThe best case will be awarded a prize09:00-09:15 Case 1 presented by Giampaolo Niccoli09:15-09:20 Discussion 09:20-09:35 Case 2 presented by Mark Thomas09:35-09:40 Discussion 09:40-09:55 Case 3 presented by Allan Bohm09:55-10:00 Discussion10:00-10:15 Case 4 presented by Giampaolo Niccoli10:15-10:20 Discussion 10:20-10:25 Voting for the best clinical case10:25-10:50 Coffee breakSESSION 9: COEXISTING ATRIAL FIBRILLATION AND CAD – Chairs: R. De Caterina and S.D. Kristensen 10:50-11:05 Stable coronary artery disease, elective stenting and atrial fibrillation – K. Huber11:05-11:10 Discussion11:10-11:25 After an ACS – R. De Caterina11:25-11:30 Discussion11:30-11:40 Best Clinical Case Prize Winner Announcement – E. Grove and M. Zimarino11:40-11:55 Closing remarks – Course Director11:45 End of course
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903 Sophia Antipolis, FR
This programme is supported by Aspen Pharma, AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Daiichi-Sankyo, in the form of unrestricted educational grants. The scientific programme has not been influenced in any way by its sponsors.
© 2017 European Society of Cardiology. All rights reserved